• 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 喝了6瓶劲酒和1斤白酒 男子手持钢锯在重庆西站撒泼遭控制 2019-06-01
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>公司动态>2009年Covidien宣布达成收购Aspect Medical Systems的最终协议

    2018微信时时彩严打吗?: 2009年Covidien宣布达成收购Aspect Medical Systems的最终协议

    Covidien2012年4月17日 15:49 点击:2496

    时时彩网络平台 www.qlgr.net
    美国Covidien 美国Aspect Medical Systems

    爱尔兰都柏林和马塞诸塞州诺伍德--(美国商业资讯)--Covidien(纽交所股票代码:COV)和Aspect Medical Systems公司(纳斯达克股票代码:ASPM)于今日宣布,前者已达成收购全球领先的脑部监控技术提供商Aspect公司的最终协议。

    两家企业的董事会全票通过了该交易,自此,Covidien的一家全资子公司将以每股12美元现金收购Aspect共价值2.1亿美元的股份,此外同时收购了Aspect的现金和短期投资。本次使用全现金要约收购以及此后第二步兼并的交易安排将受限于一些诸如监管方批准等在内的惯例性成交条件,但预计将在2009年年底前完成交易。

    Aspect创立于1987年,是公认的脑部监控技术先驱和全球市场龙头企业。其2008年的销售额达9900万美元。Aspect的主打产品--脑电双频指数(BISpectral IndEXTM或BISTM)技术--成为了第一个得到临床验证并商业化、直接计量脑麻醉剂和镇静药效果的技术。Aspect锐意创新,开发直接计量这些药效的自主技术,并提高病患的医疗质量和成本效益。BIS技术为医疗专业人员提供方便可靠的计量方法,获得每个病患所需麻醉药的精准剂量,使整体病患医疗水平得到提高。

    Covidien呼吸和监控方案部的Pete Wehrly表示:"Aspect的收购将扩大Covidien的产品线,并为公司的产品组合注入市场领先的脑监控技术。Aspect将带来先进的临床经验、富有实力的研发机构,并将我们的业务延伸到手术室中。这一收购与我们向邻近细分市场扩大的战略相一致,并将进一步帮助我们实现提高病患生活质量并改善客户结果的宗旨。"

    Aspect Medical Systems公司首席执行官Nassib Chamoun认为:"加入Covidien使Aspect获得了规模和资源,使BIS和其他Aspect产品得到加速发展,使我们向结果型研究继续投资,使我们获得相对有效性和创新,并使为改善病患结果提供产品的战略获得支持。总之,我们很荣幸成为该公司的一员,公司将与我们共同致力于实据医学并开发产品,帮助临床医生实施更高效更低成本的医护。"

    假设交易于09年12月31日完成,Covidien预计本交易所产生的一次性改制费用将摊薄公司2010财年根据一般公认会计准则计算的每股收益。以非一般公认会计准则计算且剔除改制费用计算,预计该交易将轻微摊薄2010年度每股收益;幸好Covidien目前的业务实力预期能够弥补这一摊薄。因此,Covidien预期该交易将不会对公司2010财年的销售或营业利润率前景产生实质性影响。

    一旦交易完成,Aspect的业务将作为Covidien医疗器械部血氧定量和监控产品线的一部分出现在报表中。

    关于COVIDIEN

    Covidien是一家全球领先的健康保健产品公司,致力于为改善患者的用药效果提供创新的医疗解决方案,并通过在临床领域的领导地位及卓越表现创造价值。Covidien在三大业务领域制造和销售业界领先的产品线,并提供相关服务,这三大领域包括:医疗器械、医药产品、以及医疗用品。2008年,Covidien公司的营业收入近100亿美元,公司在全球59个国家拥有41,000多名员工,其产品销往140多个国家。更多有关我们业务的信息,请登陆公司网站:www.covidien.com。

    关于ASPECT MEDICAL SYSTEMS公司

    Aspect Medical Systems公司是脑监控技术市场的全球领先企业。迄今为止,该公司的脑电双频指数(Bispectral IndexTM或BISTM)技术应用于大约3400万名病患的检测服务中,并成为了3300多篇已发表文章和摘要中的主题。入围《美国新闻与世界报道》09年7月"美国最佳医院"排名的医院中有大约78%使用了BIS技术,美国大约74%的手术室安装了该设备。在过去的12个月中,全美大约19%使用全身麻醉或深度镇静的外科手术应用了BIS技术。Aspect Medical Systems公司与9家领先的病患监控系统制造商签署了代工协议。欲了解更多资料,请登录Aspect网站://www.aspectmedical.com。

    前瞻性陈述

    本新闻稿中,非描述历史性事实的任何一项陈述可能构成《1995年私人证券诉讼改革法案》定义的前瞻性陈述。本新闻稿包含有关Covidien公司拟议收购Aspect Medical Systems, Inc.,预期进行的这项交易的时机选择,预期进行的这项交易的潜在效益,Aspect公司的临床实验、产品和候选产品以及此类产品和候选产品的潜在效益,以及预期的稀释效果的前瞻性信息。本文所含任何前瞻性陈述均以Aspect公司管理层当前观点和预期为根据,但可能受到一系列风险、不确定性和情况变化的影响,这些影响因素可能导致实际结果或行动与这些陈述所描述或默示的情况产生显著差异??赡艿贾陆窈笫导式峁氲鼻霸て诓灾钜斓囊蛩匕?,但不限于:协议完成条件的满足;将Aspect公司的业务和计划与Covidien公司的业务和产品成功整合的能力,以及做到这一点所需的时间和资源,商业及研发活动本身的不确定性,监管机构关于是否及何时批准此类候选产品应用的决定,其他可能影响此类候选产品的上市或商业潜力的事项;以及竞争性发展。这些因素以及其他因素在Covidien公司和Aspect公司向美国证券交易委员会呈报的文件中有更详细的界定和说明。我们敬告投资者,请勿过度依赖本新闻稿所含前瞻性陈述。除非法律有所规定,我们不承担任何更新这些前瞻性陈述的责任。

    非一般公认会计准则财务信息

    本新闻稿含有非一般公认会计准则财务数字。Covidien在业绩数字中包含了非一般公认会计准则数字,这一数字是Covidien一般公认会计准则财务业绩数字的补充而不应被视为一般公认会计准则财务业绩数字的替代数据或比后者更优。本新闻稿同时提供了两者之间对比。Covidien的非一般公认会计准则数字可能与其他企业所引用的定义有所不同,因此建议读者审慎阅读Covidien对于非一般公认会计准则财务数字的定义。

    另请注意,每股收益摊薄预测数字中已剔除了一次性改制费用。

    该非一般公认会计准则财务数字帮助Covidien管理层了解相对经营业绩(相比往期和预期数字)和未来前景。Covidien管理层同时在财务和经营决策中使用本非一般公认会计准则财务数字,认为该数字反映了Covidien持续经营业务的经济表现,使各期数字更具可比性。其可比性的原因在于,按照一般公认会计准则下编制的经营业绩或不时包括与Covidien业务无关的项目,而因此在一定情况下加大了对未来期间准确预测的难度。Covidien管理层认为,本非一般公认会计准则财务数字能够为投资者和其他相关方所用,帮助他们以管理层的角度了解并评估Covidien的当前经营业绩和未来前景。由于在编制过程中不包括所有影响Covidien经营的收入和费用项目,非一般公认会计准则财务数字同时具有局限性。为弥补在使用过程中的这一局限性以及其他缺陷,Covidien管理层同时将根据一般公认会计准则所编制的财务业绩数字纳入考虑范围。

    关于本次收购要约的重要信息

    本新闻稿既非购买要约,亦非对出售Aspect股份的要约的征求书。Covidien公司间接全资所有的子公司Transformer特拉华公司(Transformer Delaware Corp.,"实施合并的子公司")尚未启动本新闻稿所述的对Aspect公司股份的收购要约。

    收购要约一旦启动,"实施合并的子公司"将向美国证券交易委员会呈报一份"收购要约表"(SChedule TO)收购要约说明书及相关证据,其中包括购买邀约、转送函以及其他相关文件。收购要约开始之后,Aspect公司将向美国证券交易委员会呈报一份"14D-9表"(Schedule 14D-9)收购要约征求/推荐说明书。这些文件将包含有关Covidien公司、Aspect公司、本次交易以及其他相关事项的重要信息。这些文件发布之后,请投资者及证券持有人仔细阅读。

    投资者及证券持有人可在美国证券交易委员会维护的网站(www.sec.gov)免费获取"实施合并的子公司"和Aspect公司向美国证券交易委员会呈报的收购要约说明书、收购要约征求/推荐说明书以及其他文件的复本。另外,投资者和证券持有人还可通过下列联系方式免费获得这些文件的复本:

    Covidien

    投资者关系部

    508-452-4650

    [email protected]

    AspectMedical Systems

    投资者关系部

    1-617-559-7000

    [email protected]

    免责声明:本公告之原文版本乃官方授权版本。译文仅供方便了解之用,烦请参照原文,原文版本乃唯一具法律效力之版本。

    联系方式:

    COVIDIEN

    Eric Kraus

    企业传播部高级副总裁

    508-261-8305

    [email protected]

    Coleman Lannum, CFA

    投资者关系部副总裁

    508-452-4343

    [email protected]

    Bruce Farmer

    公关部副总裁

    508-452-4372

    [email protected]

    Brian Nameth

    投资者关系部总监

    508-452-4363

    [email protected]

    ASPECT

    J. Neal Armstrong

    副总裁兼首席财务官

    617-559-7162

     

    Covidien Announces Definitive Agreement to Acquire Aspect Medical Systems, Inc.
    DUBLIN, Ireland & NORWOOD, Mass., Sep 28, 2009 (BUSINESS WIRE) -- Covidien (NYSE: COV) and Aspect Medical Systems, Inc. (NASDAQ: ASPM) today announced that Covidien has reached a definitive agreement to acquire Aspect, a global market leader in brain monitoring technology.

    The Boards of Directors of both companies have unanimously approved the transaction, pursuant to which a wholly owned subsidiary of Covidien will pay $12.00 in cash per Aspect share for a total of approximately $210 million, net of cash and short-term investments acquired. The transaction, which will take the form of an all cash tender offer followed by a second-step merger, is subject to customary closing conditions, including receipt of certain regulatory approvals, and is expected to be completed by the end of calendar 2009.

    Founded in 1987, Aspect is recognized as a pioneer and global market leader in brain monitoring, with 2008 revenues of $99 million. Aspect's premier product -- Bispectral Index(TM) (BIS(TM)) technology -- became the first clinically proven and commercially available direct measure of the effects of anesthetics and sedatives on the brain. Aspect led the way to develop proprietary technologies that directly measure these effects and ultimately improve the quality and cost effectiveness of patient care. BIS technology is designed to allow medical professionals to reliably gauge the precise amount of anesthetic medication required by each patient, resulting in better overall patient care.

    "The acquisition of Aspect will allow Covidien to broaden its product offerings and add a market leading brain monitoring technology to its portfolio," said Pete Wehrly, President, Respiratory & Monitoring Solutions, Covidien. "Aspect will bring us enhanced clinical expertise, a strong research & development organization and expand our presence in the operating room. The acquisition is consistent with our strategy of expanding into adjacent market segments and will help us achieve our mission of enhancing the quality of life for patients and improving outcomes for our customers."

    "Joining Covidien provides Aspect with the scale and resources to accelerate growth of BIS and other Aspect products, to continue to invest in outcomes research, comparative effectiveness and innovation, and to support the strategy of providing products that are designed to improve patient outcomes," said Nassib Chamoun, President and Chief Executive Officer, Aspect Medical Systems. "Above all, we are pleased to become part of a company that shares our commitment to evidence-based medicine and the development of products that help clinicians cost-effectively deliver better care."

    Assuming a December 31, 2009, closing, Covidien expects this transaction to dilute fiscal 2010 GAAP earnings per share, primarily due to a one-time charge for restructuring. On a non-GAAP basis, excluding the restructuring charge, the transaction is expected to be slightly dilutive to 2010 earnings per share; however, the underlying strength of Covidien's existing businesses is expected to offset this dilution. As a result, Covidien does not anticipate this transaction will have a material impact on its fiscal 2010 sales or operating margin outlook.

    Once the transaction has been completed, Covidien will report the Aspect business as part of its Oximetry and Monitoring product line in the Medical Devices segment.

    ABOUT COVIDIEN

    Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2008 revenue of $10 billion, Covidien has more than 41,000 employees worldwide in 59 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

    ABOUT ASPECT MEDICAL SYSTEMS, INC.

    Aspect Medical Systems, Inc. is a global market leader in brain monitoring technology. To date, the Company's Bispectral Index (BIS) technology has been used to assess approximately 34 million patients and has been the subject of more than 3,300 published articles and abstracts. BIS technology is installed in approximately 78 percent of hospitals listed in the July 2009 U.S. News and World Report ranking of America's Best Hospitals and in approximately 74 percent of all U.S. operating rooms. In the last twelve months, BIS technology was used in approximately 19 percent of all U.S. surgical procedures requiring general anesthesia or deep sedation. Aspect Medical Systems has OEM agreements with nine leading manufacturers of patient monitoring systems. For more information, visit Aspect's Web site at //www.aspectmedical.com.

    FORWARD-LOOKING STATEMENTS

    Any statements contained in this communication that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. This release contains forward-looking information about Covidien's proposed acquisition of Aspect Medical Systems, Inc., the timing of the anticipated transaction, the potential benefits of the anticipated transaction, Aspect's clinical trials, products and product candidates and the potential benefits of such products and product candidates, and expected dilutive effect. Any forward-looking statements contained herein are based on Covidien's and Aspect's management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or actions to differ materially from what is expressed or implied by these statements. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, the satisfaction of conditions to closing the agreement; the ability to successfully integrate Aspect's operations and programs with Covidien's and the time and resources required to do so, the uncertainties inherent in commercial, research and development activities, decisions by regulatory authorities regarding whether and when to approve any applications for such product candidates and other matters that could affect the availability or commercial potential of such product candidates; and competitive developments. These and other factors are identified and described in more detail in Covidien's and Aspect's filings with the SEC. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. We disclaim any obligation to update these forward-looking statements other than as required by law.

    NON-GAAP Financial Information

    This release contains a non-GAAP financial measure. This non-GAAP financial measure, which is used a measure of Covidien's performance, should be considered in addition to, not as a substitute for, or superior to, measures of Covidien's financial performance prepared in accordance with GAAP. A reconciliation of this non-GAAP financial measure to GAAP is provided in the text of this release. Covidien's non-GAAP measures may be defined differently than similar terms used by other companies, and accordingly, care should be exercised in understanding how Covidien defines its non-GAAP financial measures.

    Specifically, any one-time charge for restructuring is excluded from the projected earnings per share dilution.

    Covidien management uses this non-GAAP financial measure to gain an understanding of its comparative operating performance (when comparing such results with previous periods or forecasts) and future prospects. This non-GAAP financial measure is also used by Covidien's management in their financial and operating decision-making because management believes it reflects the underlying economics of Covidien's ongoing business in a manner that allows meaningful period-to-period comparisons. Such comparisons may be more meaningful because operating results presented under GAAP may include, from time to time, items that are not necessarily relevant to understand Covidien's business and may, in some cases, be difficult to forecast accurately for future periods. Covidien's management believes that this non-GAAP financial measure provides useful information to investors and others in understanding and evaluating Covidien's current operating performance and future prospects in the same manner as management does if they so choose. Non-GAAP financial measures have limitations, however, because they do not include all items of income and expense that affect Covidien's operations. Covidien's management compensates for this and other limitations by also considering Covidien's financial results as determined in accordance with GAAP.

    IMPORTANT INFORMATION ABOUT THE TENDER OFFER

    This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Aspect. Transformer Delaware Corp. (the "Merger Sub"), an indirect, wholly-owned subsidiary of Covidien, has not commenced the tender offer for the shares of Aspect stock described in this press release.

    Upon commencement of the tender offer, the Merger Sub will file with the SEC a tender offer statement on Schedule TO and related exhibits, including the offer to purchase, letter of transmittal, and other related documents. Following commencement of the tender offer, Aspect will file with the SEC a tender offer solicitation/recommendation statement on Schedule 14D-9. These documents will contain important information about Covidien, Aspect, the transaction and other related matters. Investors and security holders are urged to read each of these documents carefully when they are available.

    Investors and security holders will be able to obtain free copies of the tender offer statement, the tender offer solicitation/recommendation statement and other documents filed with the SEC by the Merger Sub and Aspect through the web site maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of these documents by contacting:

    Covidien
    Investor Relations
    508-452-4650

    [email protected]

     
    or
     
    Aspect Medical Systems
    Investor Relations
    1-617-559-7000

    [email protected]

    SOURCE: Covidien

    COVIDIEN
    Eric Kraus
    Senior Vice President
    Corporate Communications
    508-261-8305
    [email protected]
    or
    Coleman Lannum, CFA
    Vice President
    Investor Relations
    508-452-4343
    [email protected]
    or
    Bruce Farmer
    Vice President
    Public Relations
    508-452-4372
    [email protected]
    or
    Brian Nameth
    Director
    Investor Relations
    508-452-4363
    [email protected]
    or
    ASPECT
    J. Neal Armstrong
    Vice President and CFO
    617-559-7162

    (来源: Covidien )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 喝了6瓶劲酒和1斤白酒 男子手持钢锯在重庆西站撒泼遭控制 2019-06-01
  • 江西快三投注网址 双色球开奖现场直播 十一运夺金历史 河北十一选五遗漏什么时候出 白小姐透码201913期 总进球奖金计算器 山东时时彩开奖结果 竞彩混合过关奖金算法 0.01—0.1元捕鱼 六肖中特期期准免费 福彩12选5走势图 22选5开奖结果黑龙江 竞彩158app 大小球彩票软件 急速赛车计划